Immunodeficiency Virus Patents (Class 424/148.1)
-
Patent number: 6703019Abstract: The subject application discloses methods and compositions for the targeted detection and/or inhibition of an intracellular protein in a cell by contacting the cell with a cationized antibody which reacts specifically with the intracellular protein. An example of an intracellular protein which can be inhibited in this manner is the Tat protein which is encoded by the HIV-1 virus.Type: GrantFiled: September 17, 1997Date of Patent: March 9, 2004Inventor: Bernard Malfroy-Camine
-
Patent number: 6673342Abstract: Disclosed are compositions and methods of use that comprise engineered IgA antibodies that, when administered to a host are secreted across the epithelium into the mucosal barriers of the body providing external passive immunotherapy against agents such as viral, bacterial and eukaryotic pathogens. Also disclosed are mini antibodies comprising the minimal transcytosis domains.Type: GrantFiled: May 16, 2000Date of Patent: January 6, 2004Assignees: Bond of Regents, The University of Texas System, The United States of America as represented by the Department of Health and Human ServicesInventors: J. Donald Capra, Jonathan M. Hexham, Leon N. Carayannopoulos, Edward E. Max
-
Publication number: 20030187247Abstract: The present invention describes human monoclonal antibodies which immunoreact with and neutralize human immunodeficiency virus (HIV). Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell line for producing the monoclonal antibodies.Type: ApplicationFiled: December 12, 2001Publication date: October 2, 2003Applicant: The Scripps Research InstituteInventors: Dennis R. Burton, Carlos F. Barbas, Richard A. Lerner
-
Patent number: 6623738Abstract: The invention provides methods and compositions relating to two classes of semaphorin receptors, SR1 and SR2. The polypeptides may be produced recombinantly from transformed host cells from the disclosed SR encoding nucleic acids or purified from human cells. The invention provides isolated SR hybridization probes and primers, capable of specifically hybridizing with the disclosed SR genes. SR-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.Type: GrantFiled: November 12, 1999Date of Patent: September 23, 2003Assignee: The Regents of the University of CaliforniaInventors: Marc Tessier-Lavigne, Zhigang He, Hang Chen
-
Patent number: 6610833Abstract: Disclosed herein are hydridoma cell lines producing monoclonal human natural IgM antibodies and methods of use thereof. The antibodies are the monoclonal equivalents of circulating human natural antibodies. Also disclosed herein are pharmaceutical formulations and methods for treating HIV-1 infected individuals using the monoclonal human natural antibodies.Type: GrantFiled: December 28, 1999Date of Patent: August 26, 2003Assignee: The Institute for Human Genetics and BiochemistryInventor: Toby C. Rodman
-
Patent number: 6596478Abstract: The present invention comprises methods, devices and compositions for detection of endogenous retroviruses found in xenotransplant materials. The methods and compositions are suited for detection of endogenous type-C retroviruses and in particular, for porcine endogenous retrovirus, PERV.Type: GrantFiled: March 12, 2001Date of Patent: July 22, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Walid M. Heneine, William M. Switzer, Paul A. Sandstrom, Aprille L. Matthews, Thomas M. Folks
-
Patent number: 6565849Abstract: Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.Type: GrantFiled: March 2, 2001Date of Patent: May 20, 2003Assignee: MedImmune, Inc.Inventor: Scott Koenig
-
Patent number: 6545128Abstract: The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor protein-1 (BI-1; SEQ ID NO: 1) or Bax inhibitor protein-2 (BI-2; SEQ ID NO: 4), nucleic acid molecules complementary thereto (SEQ ID NO: 2 and SEQ ID NO: 5, respectively), portions of such nucleic acid molecules, vectors containing the nucleic acid molecules, and host cells containing the vectors. The invention also provides methods of using such nucleic acid molecules to identify the presence of a nucleic acid molecule encoding a Bax inhibitor protein in a sample or to increase or decrease the level of expression of a Bax inhibitor protein in a cell. In addition, the invention provides substantially purified BI-1 (SEQ ID NO: 3) and BI-2 (SEQ ID NO: 6) polypeptides, portions of such polypeptides, and antibodies specific for BI-1 or BI-2.Type: GrantFiled: July 6, 2000Date of Patent: April 8, 2003Assignee: The Burnham InstituteInventors: John C. Reed, Qunli Xu
-
Patent number: 6503753Abstract: Human immunodeficiency virus (HIV) comprising reverse transcriptase inactivated by photoinactivation. The inactivated virus may be more safely handled, stored, and analyzed, used in diagnostic procedures and kits, and may be used as an immunogen to evoke an immune response. The immune response may protect an individual from challenges with live virus. Alternatively, the inactivated HIV particles may be used to augment the immune response to HIV in an infected individual.Type: GrantFiled: August 14, 2000Date of Patent: January 7, 2003Inventor: Adan Rios
-
Publication number: 20020197711Abstract: Disclosed is a recombinant attenuated coxsackievirus B4 virion which is engineered to contain a heterologous nucleic acid within the open reading frame of its genome, wherein the heterologous nucleic acid encodes a heterologous polypeptide which is expressed by the virion. Specific examples of attenuated coxsackievirus B4 virions suitable for use in the present invention are CB4-P and JVB. In one embodiment the heterologous nucleic acid is inserted into the P1 region of the genome such that the heterologous polypeptide is expressed as a fusion of a viral capsid protein. Methods of use of the recombinant attenuated coxsackievirus B4 virion include inducing an immune response in an individual to the heterologous polypeptide contained therein.Type: ApplicationFiled: June 12, 2001Publication date: December 26, 2002Inventors: Arlene I. Ramsingh, Sadia S. Halim
-
Publication number: 20020155428Abstract: A novel immunodeficiency virus is disclosed which has the designation MVP-5180/91 and which has been deposited with the European Collection of Animal Cell Cultures (ECACC) under No. V 920 52 318. The characteristics antigens which can be obtained from it and which can be employed for detecting antibodies against retroviruses which are associated with immunodeficiency diseases are also disclosed, as are the DNA and amino acid sequences of the virus.Type: ApplicationFiled: June 22, 2001Publication date: October 24, 2002Applicant: Dade Behring Marburg GmbH.Inventors: Lutz G. Guertler, Josef Eberle, Albrecht V. Brunn, Stefan Knapp, Hans-Peter Hauser
-
Publication number: 20020123036Abstract: The present invention relates to a method for analyzing the phenotypic characteristics shown by certain virus strains, particularly human immnunodeficiency viruses, involving the construction of a recombinant virus obtained by homologous recombination.Type: ApplicationFiled: March 27, 2001Publication date: September 5, 2002Inventors: Francois Clavel, Esther Race, Veronique Obry, Fabrizio Mammano, Elisabeth Dam, Virginie Trouplin
-
Patent number: 6440416Abstract: A method of stimulating an immune response in a human against malignant cells or an infectious agent comprises the step of administering to the human an immunogenic amount of a primate anti-idiotype antibody or antibody fragment that acts as an immunogenic functional mimic of an antigen produced by or associated with a malignant cell or an infectious agent. Sub-human primate anti-idiotype antisera, especially from baboons, are preferred. Such anti-idiotype antibodies are used to make vaccines for inducing preventive immunity or a therapeutic immune response against tumors, viruses, bacteria, rickettsia, mycoplasma, protozoa, fungi and multicellular parasites.Type: GrantFiled: January 2, 1992Date of Patent: August 27, 2002Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen
-
Publication number: 20020106375Abstract: A new factor, Factor C, is produced by the activated-expanded autologous cells of cancer patients, HIV-1 infected patients, CFS patients, healthy patients, etc. Factor C has a molecular weight of about 70,000 to 80,000 daltons, is heat stable, has an amino acid sequence that is absent from the National Center for Biotechnology Information database, and whose amino acid sequence is not homologous to TNF family ligands. Factor C is derived from CD4 cells in a much greater quantity than from CD8 cells, and is derived from lymph cells in a greater quantity than from PBL cells. A double activation and expansion (activation-expansion) process using immobilized and soluble anti-CD3 mAb makes such Factor C. Factor C appears to inhibit transcription in virally-infected and tumor cells, and stimulates the proliferation of normal lymphocytes.Type: ApplicationFiled: November 30, 2000Publication date: August 8, 2002Inventors: Pierre L. Triozzi, John L. Ridihalgh, Herbert S. Bresler
-
Publication number: 20020106374Abstract: This invention provides a composition which comprises an admixture of three compounds, wherein: (a) one compound is an antibody which binds to a CCR5 receptor; (b) one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope glycoprotein to CD4 on the surface of the CD4+ cell; and (c) one compound retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate; wherein the relative mass ratio of any two of the compounds in the admixture ranges from about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell.Type: ApplicationFiled: July 25, 2001Publication date: August 8, 2002Inventors: William C. Olson, Paul J. Maddon
-
Publication number: 20020098189Abstract: High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.Type: ApplicationFiled: March 1, 2001Publication date: July 25, 2002Inventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Publication number: 20020095027Abstract: A purified polypeptide having an epitope of an antigenic polypeptide of FIV.Type: ApplicationFiled: September 25, 2001Publication date: July 18, 2002Inventors: Philip R. Andersen, Thomas P. O'Connor, Quentin J. Tonelli
-
Publication number: 20020086020Abstract: This invention relates to methods of increasing the half-life of a viral-specific ligand on a mucosal membrane by modifying the viral-specific ligand to bind the bacteria colonized on the mucosal membrane. The invention also provides a chimeric molecule comprising a viral-specific ligand and a bacterial-specific ligand.Type: ApplicationFiled: January 10, 2002Publication date: July 4, 2002Applicant: OSEL, INC.Inventor: Peter P. Lee
-
Publication number: 20020086283Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates. The invention also relates to a method of inducing anti-HIV antibodies using same.Type: ApplicationFiled: September 24, 2001Publication date: July 4, 2002Inventors: Barton F. Haynes, Dhavalkumar D. Patel, Munir Alam, Hua-Xin Liao
-
Patent number: 6395275Abstract: The present invention describes synthetic human monoclonal antibodies that immunoreact with and neutralize human immunodeficiency virus (HIV). The synthetic monoclonal antibodies of this invention exhibit enhanced binding affinity and neutralization ability to gp120. Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell lines for producing the monoclonal antibodies.Type: GrantFiled: July 6, 2000Date of Patent: May 28, 2002Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, Dennis R. Burton, Richard A. Lerner
-
Publication number: 20020058797Abstract: A monoclonal antibody specific to Nap was prepared by using a crude membrane fraction from a cell line which has a high affinity to Nef as an antigen. A cDNA clone which encodes Nap was obtained by screening a cDNA library of said cell line utilizing the specific antibody. The nucleotide sequence of this cDNA was elucidated whereupon the full amino acid sequences of human Nap was identified. Since the anti-Nap monoclonal antibody inhibits the binding of Nef to Nap, it can be used as a new therapeutic agent for AIDS. In addition, it can be applied for the diagnosis of AIDS by clarifying the relation between the expression of Nap and the development of AIDS. Nap can be utilized for binding experiments to Nef.Type: ApplicationFiled: July 5, 2001Publication date: May 16, 2002Applicant: Nippon Zoki Pharmaceutical Co. Ltd.Inventors: Yoichi Fujii, Kaori Otake
-
Publication number: 20010010901Abstract: The present invention provides an anti-idiotypic antibody having specific reactivity with an idiotope common to more than one type of anti-HIV-1 antibody, and having no specific reactivity with non-HIV-1 antibodies. The present invention provides methods of diagnosis, monitoring and treatment of HIV-related diseases through the use of this antibody or related compounds.Type: ApplicationFiled: February 28, 2001Publication date: August 2, 2001Inventors: Sybille Muller, Haitao Wang
-
Patent number: 6261558Abstract: The present invention describes synthetic human monoclonal antibodies that immunoreact with and neutralize human immunodeficiency virus (HIV). The synthetic monoclonal antibodies of this invention exhibit enhanced binding affinity and neutralization ability to gp120. Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as cell lines for producing the monoclonal antibodies.Type: GrantFiled: February 20, 1996Date of Patent: July 17, 2001Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, Dennis R. Burton, Richard A. Lerner
-
Patent number: 6248332Abstract: Disclosed are methods of stimulating in a subject an immune response to an antigen to which the immune response is targeted. This method includes the step of administering to the subject a binding agent which binds a surface receptor of an antigen-presenting cell, in some instances without being blocked substantially by the natural ligand for the surface receptor, and an antigen to which the immune response is targeted, in a physiologically acceptable medium to the subject. Also disclosed are molecular complexes including the binding agent coupled to an antigen.Type: GrantFiled: May 26, 1994Date of Patent: June 19, 2001Assignee: Medarex, Inc.Inventors: Jean Loup Romet-Lemonne, Michael W. Fanger, Paul M. Guyre, Edmund J. Gosselin
-
Patent number: 6241986Abstract: Human monoclonal antibodies specific for the CD4-binding domain of HIV gp120 are useful in the neutralization of HIV and in the prevention of HIV infection and the treatment of a subject infected with HIV. Such antibodies and heterohybridomas producing them are disclosed. Synergistic mixtures of at least two human monoclonal antibodies specific for two different epitopes of gp120 are used to neutralize HIV, to prevent HIV infection and to treat a subject infected with HIV. In this synergistic mixture, one antibody has broad HIV group specificity, and is preferably specific for the CD4-binding domain. The other antibody is preferably specific for the V3 loop and has a range of neutralizing activity such that it neutralizes virus of the MN strain, MN-like families, and widely divergent HIV-1 isolates which are members of various V3 lop classes.Type: GrantFiled: March 21, 1994Date of Patent: June 5, 2001Assignee: New York UniversityInventors: Susan Zolla-Pazner, Miroslaw K. Gorny, Sylwia Karwowska, Aby Buchbinder
-
Patent number: 6228361Abstract: The present invention provides a human-mouse myeloma analog, designated HMMA 2.11TG/O, which has been deposited with the American Type Culture Collection (ATCC) under Accession Number HB 9583. The invention also provides a hybridoma designated F 105, which also has been deposited with the ATCC under Accession Number HB 10363. The invention also concerns a monoclonal antibody-producing hybridoma produced by the fusion of the human-mouse myeloma analog and an antibody-producing cell. Other embodiments of the invention provide a method for producing a monoclonal antibody-producing hybridoma which comprises fusing the human-mouse myeloma analog with a human antibody-producing cell and a therapeutic method for treating a subject having a pathogen- or tumor-related disease which comprises administering to the subject a monoclonal antibody specific for the disease produced by the monoclonal antibody-producing hybridoma.Type: GrantFiled: June 2, 1995Date of Patent: May 8, 2001Assignee: Roger Williams General HospitalInventor: Marshall R. Posner
-
Patent number: 6190871Abstract: The invention features immunoreagents which neutralize the Human Immunodeficiency Virus Type 1 (HIV-1) by binding to a novel conserved epitope of the HIV-1 gp120. These immunoreagents exhibit a broad neutralizing effect upon HIV attachment to host cells, and are therefore useful in the detection, prevention, amelioration and treatment of HIV disease, primarily AIDS (Acquired Immunodeficiency Syndrome) and ARC (AIDS Related Complex). More particularly, the invention relates to novel human monoclonal antibodies selectively reactive to a conserved conformation dependent determinant of the HIV-1 gp120, derivatives thereof, cell lines that produce these antibodies, and the use of the monoclonal antibodies and their derivatives for the detection, prevention, amelioration and treatment of HIV related disease.Type: GrantFiled: March 11, 1999Date of Patent: February 20, 2001Assignee: Cedars-Sinai Medical CenterInventors: David D. Ho, James E. Robinson